'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Onyx Biotec Limited
ONYX (NSE) · ONYX (BSE 212187) · ISIN INE0WVU01018 · Pharmaceuticals · listed 2024
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
No quarterly results stored for this company yet.
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹55.41 cr | ₹15.17 cr | ₹95.15 cr |
| 30 Sep 2025 standalone | ₹54.72 cr | ₹15.73 cr | ₹92.12 cr |
| 31 Mar 2025 standalone | ₹55.62 cr | ₹12.46 cr | ₹91.25 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 41.74% | 0.22% | 2.39% | 58.26% |
Latest filings
- Annual Report FY2025-26 (Revised) 7 September 2026 · NSE
- Annual Report FY2025-26 (New) 5 September 2026 · NSE
- Onyx Biotec Limited has informed the Exchange regarding Outcome of Board Meeting held on May 26, 2026. 26 May 2026 · NSE
- Onyx Biotec Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 14 May 2026 · NSE
- Onyx Biotec Limited has informed the Exchange regarding Outcome of Board Meeting held on March 26, 2026. 26 March 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.